OBJECTIVE: To reveal the outcomes of initial active surveillance (AS), followed by deferred systemic target therapy, in a subpopulation of patients with indolent metastatic renal cell carcinoma (mRCC). METHODS: We retrospectively reviewed the clinical and pathologic data of patients with mRCC, who initially were monitored by planned AS before systemic therapy because of their preference and asymptomatic or slowly progressive disease, at our institution between 2000 and 2011. The primary outcome measures were progression-free survival (PFS) and overall survival (OS). RESULTS: Twenty-nine patients with a metastatic lesion at start of AS were eligible for this analysis. The median age at the start of AS was 69 years. Of these patients, 65% had recurrent disease and 35% were in stage IV. All patients had undergone nephrectomy and 86% had clear-cell carcinoma. No patients were categorized into a poor risk according to Memorial Sloan-Kettering Cancer Center (MSKCC) and Heng criteria. The median follow-up period was 35.4 months. Disease progression was observed in 72% of patients, but only 14% died during the follow-up period. The median PFS time was 26.1 months. After disease progression was observed, only 58% of these patients received treatment. The median OS had not been reached, but 12, 24, and 48 months OS rates were 96.4%, 88.7%, and 83.8%, respectively. CONCLUSION: PFS and OS of patients who underwent AS were acceptable. AS might be a reasonable approach, particularly for patients with prolonged, indolent course of the disease. Further observational studies with a larger sample size might be needed.
OBJECTIVE: To reveal the outcomes of initial active surveillance (AS), followed by deferred systemic target therapy, in a subpopulation of patients with indolent metastatic renal cell carcinoma (mRCC). METHODS: We retrospectively reviewed the clinical and pathologic data of patients with mRCC, who initially were monitored by planned AS before systemic therapy because of their preference and asymptomatic or slowly progressive disease, at our institution between 2000 and 2011. The primary outcome measures were progression-free survival (PFS) and overall survival (OS). RESULTS: Twenty-nine patients with a metastatic lesion at start of AS were eligible for this analysis. The median age at the start of AS was 69 years. Of these patients, 65% had recurrent disease and 35% were in stage IV. All patients had undergone nephrectomy and 86% had clear-cell carcinoma. No patients were categorized into a poor risk according to Memorial Sloan-Kettering Cancer Center (MSKCC) and Heng criteria. The median follow-up period was 35.4 months. Disease progression was observed in 72% of patients, but only 14% died during the follow-up period. The median PFS time was 26.1 months. After disease progression was observed, only 58% of these patients received treatment. The median OS had not been reached, but 12, 24, and 48 months OS rates were 96.4%, 88.7%, and 83.8%, respectively. CONCLUSION: PFS and OS of patients who underwent AS were acceptable. AS might be a reasonable approach, particularly for patients with prolonged, indolent course of the disease. Further observational studies with a larger sample size might be needed.
Authors: Alberto Diaz de Leon; Ali Pirasteh; Daniel N Costa; Payal Kapur; Hans Hammers; James Brugarolas; Ivan Pedrosa Journal: Radiographics Date: 2019-06-14 Impact factor: 5.333
Authors: Brian I Rini; Tanya B Dorff; Paul Elson; Cristina Suarez Rodriguez; Dale Shepard; Laura Wood; Jordi Humbert; Linda Pyle; Yu-Ning Wong; James H Finke; Patricia A Rayman; James M G Larkin; Jorge A Garcia; Elizabeth R Plimack Journal: Lancet Oncol Date: 2016-08-03 Impact factor: 54.433
Authors: Michael R Harrison; Brian A Costello; Nrupen A Bhavsar; Ulka Vaishampayan; Sumanta K Pal; Yousef Zakharia; Heather S L Jim; Mayer N Fishman; Ana M Molina; Christos E Kyriakopoulos; Che-Kai Tsao; Leonard J Appleman; Benjamin A Gartrell; Arif Hussain; Walter M Stadler; Neeraj Agarwal; Russell K Pachynski; Thomas E Hutson; Hans J Hammers; Christopher W Ryan; Brant A Inman; Jack Mardekian; Azah Borham; Daniel J George Journal: Cancer Date: 2021-03-25 Impact factor: 6.860
Authors: Christopher J D Wallis; Giacomo Novara; Laura Marandino; Axel Bex; Ashish M Kamat; R Jeffrey Karnes; Todd M Morgan; Nicolas Mottet; Silke Gillessen; Alberto Bossi; Morgan Roupret; Thomas Powles; Andrea Necchi; James W F Catto; Zachary Klaassen Journal: Eur Urol Date: 2020-05-03 Impact factor: 20.096